
Your Feed
A Unique BTK Inhibitor, Pirtobrutinib for Patients with Pretreated CLL | Jeff Sharman, MD | #ASH24
A Unique BTK Inhibitor, Pirtobrutinib for Patients with Pretreated CLL | Jeff Sharman, MD | #ASH24
Duvelisib + Venetoclax: A Time-Limited, All Oral Option for CLL | Jennifer Crombie, MD | #ASH24
Duvelisib + Venetoclax: A Time-Limited, All Oral Option for CLL | Jennifer Crombie, MD | #ASH24
Promising Results for Odronextamab in Post CAR T Patients with DLBCL | Jennifer Crombie, MD | #ASH24
Promising Results for Odronextamab in Post CAR T Patients with DLBCL | Jennifer Crombie, MD | #ASH24
Analyzing the Impact of Smoking on Myelodysplastic Syndromes | Sangeeth Venugopal, MD | #ASH24
Analyzing the Impact of Smoking on Myelodysplastic Syndromes | Sangeeth Venugopal, MD | #ASH24
Adding Venetoclax to 7+3 Chemotherapy in Newly Diagnosed AML | Ioannis Mantzaris, MD | #ASH24
Adding Venetoclax to 7+3 Chemotherapy in Newly Diagnosed AML | Ioannis Mantzaris, MD | #ASH24
Understanding the ASH Research Collaborative- COSMIC Study | Saad Usmani, MD | #ASH24
Understanding the ASH Research Collaborative- COSMIC Study | Saad Usmani, MD | #ASH24
Belantamab + Standard of Care for Newly Diagnosed Myeloma (DreaMM-9) | Saad Usmani, MD | #ASH24
Belantamab + Standard of Care for Newly Diagnosed Myeloma (DreaMM-9) | Saad Usmani, MD | #ASH24
Social Determinants of Health Impact Myeloma FISH Testing | Amy Pierre, MSN, RN, ANP-BC | #ASH24
Social Determinants of Health Impact Myeloma FISH Testing | Amy Pierre, MSN, RN, ANP-BC | #ASH24
Dara-CyBorD vs CyBorD in Newly Diagnosed AL Amyloidosis| Hans Lee, MD | #ASH2024



